Haemostatic agent

FIELD: pharmaceutical industry, in particular haemostatic agent.

SUBSTANCE: claimed agent represents aqueous solution, containing 2-150 g of zinc polyacrylate, 10-100 g sodium alginate and 1-30 of acetic acid in 1 l of distilled water. Agent of present invention being in contact with blood and tissues provides film formation 30 s.

EFFECT: haemostatic agent of improves quality.

 

The invention relates to medicine and can be used in surgical practice.

Known and widespread in the U.S. and Europe means having the ability to stop bleeding and glue tissue fibrin glue (V.Tilsver, N.Heimburgen, U.Becker et. al Gerinnungs fur diagnostik Diagnose und Therapie, Behringwerke A.G. 1986, Marburg/Fankfurt/M). It is a system consisting of two vials, one of them includes thrombin (400-600 ME) and calcium chloride (40 mmol/l), the second - fibrinogen (65-115 mg), factor X111 (40-80 IU), progeny (1000 KIE). If there is bleeding surface is dry and the wound is inflicted solutions from both bottles. As a result, the thrombin and calcium contribute to the transition of fibrinogen into fibrin, factor XIII (activated calcium strengthens strands of fibrin, and progeny protects obtained fibrin clot from fibrinolysis.

Fibrin glue has been widely used not only to stop bleeding, but also for bonding fabrics (along with sutures (stitches) in skin grafting, rupture of the liver, spleen, pancreas, bonding connective tissue during cataract surgery, tympanoplasty, closing defects after tumor resection, the bonding presented fragments and other

However, fibrin glue has a number of disadvantages, it is composed of proteins, the term storage is of which just 2 years. It stops bleeding and causes bonding of tissues only after prior drying of the surface. It is a favorable factor for the growth of microorganisms due to the fact that the adhesive contains proteins. It can be a cause of allergic reactions. Time stop bleeding using fibrin glue 150 seconds. However, it does not provide strong bonding to each other damaged tissues, bonding substantially prevents leakage of blood.

In connection with the above we offer a new original hemostatic adhesive, which is an aqueous solution containing 2-15% zinc polyacrylate, 1-10% of sodium alginate and 0.1-3% acetic acid. For its preparation 10-100 g algenia sodium, 20-150 g of zinc polyacrylate and 1-30 ml of acetic acid restauraut in 1 l of distilled types.

Proposed hemostatic adhesive stops bleeding, forming upon contact with blood and tissues of the film for 30 sec.

Glue is applied to the wound from a single syringe, evenly filling the wound surface, without draining the last.

Unlike expensive fibrin glue it consists of industrially produced ingredients. Can be stored at room temperature for 5 years. Thus, it is convenient to use in the military field, in the practice of the Ministry. He passes well through the probe and therefore can be used in endoscopic practice.

Example 1

Experiments to study the effect of hemostatic adhesive on the function of hemostasis was carried out in laboratory conditions on rabbits breed "chinchilla" of both sexes weighing 2000-4000, the Experiments on the evaluation of the hemostatic effect of various drugs was performed under hypentelium anesthesia (2-4 ml of 0.1% solution intravenously, and then up to 6-10 ml of 0.1% solution intraperitoneally), Performed laparotomy, using longitudinal section along the white line of the abdomen. In the wound taken out intestines, limiting its wipes moistened with warm saline solution, and the front surface of the liver. With the help of a special device-limiter sharp razor inflicted superficial wound of the liver about 1.5 cm square and a depth of about 0.1 see Stop developed capillary-parenchymal bleeding is performed by uniform application of 1 ml of hemostatic adhesive containing 2% zinc polyacrylate 1% algenia sodium and 0.1% acetic acid, after 32 seconds of a dense film of glue, which is not washed off the blood. Well adhesive to the wound surface. When the membrane is removed, the bleeding is not renewed. As control was used to stop bleeding by tightly pressed to the wound surface pad of gauze wipes. When the bleeding stopped for 300 seconds.

Example 2

p> Experiments to study the effect of hemostatic adhesive on the function of hemostasis was carried out in laboratory conditions on rabbits breed "chinchilla" of both sexes weighing 2000-4000, the Experiments on the evaluation of the hemostatic effect of various drugs was performed under hypentelium anesthesia (2-4 ml of 0.1% solution intravenously, and then up to 6-10 ml of 0.1% solution intraperitoneally). Performed laparotomy, using longitudinal section along the white line of the abdomen. In the wound taken out intestines, limiting it wipes moistened with warm saline solution, made the cut in two segments of the colon and put the anastomosis side-to-side. On the seam evenly applied 1 ml geochemische glue containing 15% zinc polyacrylate, 10% of sodium alginate and 3% acetic acid, 20 seconds of a dense film, which is not washed off the blood. Well adhesive to the wound surface. When the membrane is removed, the bleeding is not renewed. As control was used to stop bleeding by tightly pressed to the wound surface pad of gauze wipes. The bleeding stopped for 240 seconds.

Example 3

Experiments on the learning effects of the hemostatic adhesive on the function of hemostasis was carried out in laboratory conditions on rabbits breed "chinchilla" of both sexes weighing 2000-4000, the Experiments on the evaluation gamestation is one effect of the different drugs was performed under hypentelium anesthesia (2-4 ml of 0.1% solution intravenously, and then to 6-10 ml of 0.1% solution intraperitoneally). Performed laparotomy, using longitudinal section along the white line of the abdomen. In the wound gall bladder taken out and made cholecystectomy from the bottom. For the final hemostasis in the bed of the gallbladder evenly applied 1 ml of hemostatic adhesive containing 8% zinc polyacrylate, 5% of sodium alginate and 1.5% acetic acid. After 29 seconds of a dense film, which is not washed off the blood. Well adhesive to the wound surface. When the membrane is removed, the bleeding is not renewed. As control was used to stop bleeding by tightly pressed to the wound surface pad of gauze wipes. The bleeding stopped for 350 seconds.

The hemostatic agent on the basis of alginate, wherein the solution containing the sodium alginate 10-100 g, 20-150 g of zinc polyacrylate and 1-30 ml of acetic acid in 1 l of distilled water.



 

Same patents:
Hemostatic glue // 2270016

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a hemostatic agent able to stop bleedings and to glue tissues. Proposed glue represents an aqueous solution containing 50-200 g of sodium alginate, 150-200 g of feracryl and distilled water, up to 1 l. Invention provides enhancing the hemostatic activity. Time for film formation in contact of agent with blood and tissues is 30 s.

EFFECT: improved properties of glue.

3 ex

Hemostatic glue // 2270015

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to hemostatic glue. Glue comprises an aqueous solution containing 20-150 g of polyacrylate zinc, 1-30 ml of acetic acid and 1-100 g of cellulose in 1 l of distilled water. Glue shows capacity to stop bleedings and to glue tissues. Invention provides stopping bleeding and formation of film in contact with blood and tissues for 60 s.

EFFECT: enhanced effectiveness and valuable properties of glue.

3 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to compound of the formula (I): that are useful as antagonists of prostaglandin IP (I2 or PGI2). Invention proposes compound of the formula (I) wherein each R1, R2 and R3 means independently in each case aryl or heteroaryl; R4 means -COOH or tetrazolyl; A, B, m, p, q, n and r are determined in the invention description. Also, invention relates to separated isomers, racemic or nonracemic mixtures of isomers and to their pharmaceutically acceptable salts or solvates also. Also, invention relates to pharmaceutical compositions comprising indicated compounds, to a method for their preparing and using as therapeutic agents. Invention provides the development of pharmaceutical composition possessing property of antagonists of IP wherein antagonists of these receptors can prevent states associated with excessive bleeding, for example, (but not only) hemophilia and hemorrhage and relieve septic shock-associated hypotension and diminish formation of edemas.

EFFECT: valuable medicinal properties of compounds.

28 cl, 15 sch, 29 ex

FIELD: organic chemistry, chemical technology.

SUBSTANCE: invention relates to novel perfluorinated cycle-containing tertiary amines of the general formula (1): wherein n = 1; m = 2 or 3; X means or and to a mixture of perfluorinated cycle-containing tertiary amines of the general formula (1) wherein n = 1; m = 2 or 3; X means or where at n = 1 Y means CF3 and at n = 2 Y means F as a base for gas-transferring emulsions. Proposed compounds are similar by their physicochemical properties, in particular, by critical temperature dissolving in hexane. Properties of these compounds provide the improved homogeneity of fluorocarbon phase of emulsions and to enhance stability of emulsion particles stabilized with block-copolymer of ethylene oxide and propylene oxide and in the absence of toxicity for small and large animals. Also, invention relates to a method for preparing perfluorinated cycle-containing tertiary amines of the general formula (1) by electrochemical fluorination of p-piperidinoheptafluorotoluene in anhydrous hydrogen fluoride.

EFFECT: improved preparing method and valuable properties of compounds.

4 cl, w dwg, 3 tbl, 4 ex

Hemostatic glue // 2262937

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to hemostatic glue. Hemostatic glue represents an aqueous solution containing 10-100 g of cellulose, 1-30 ml of acetic acid and 1-150 g of feracryl in 1 l of distilled water. Invention provides cessation of bleeding and film formation in contact of this glue with blood and tissues for 30 s.

EFFECT: improved and valuable medicinal properties of glue.

3 ex

Hemostatic glue // 2257901

FIELD: bleeding suppression facilities.

SUBSTANCE: invention provides hemostatic glue capable of stopping bleeding and joining tissues, which is aqueous solution containing sodium alginate, acetic acid, and cellulose in specified proportions. Formation of tight film on wound surface takes 62 sec.

EFFECT: enabled application of glue onto wound from one syringe, while uniformly filling wound surface without drying of the latter.

3 ex

Hemostatic glue // 2256448

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to hemostatic glue able to stop bleeding and to glue tissues. Glue represents an aqueous solution containing 1-10% of sodium alginate, 0.1-3% of acetic acid and 0.1-15% of feracryl. Applying glue provides ceasing bleeding by formation film after contact with blood and tissues for 30 s. Glue can be stored at room temperature for 3 years.

EFFECT: valuable medicinal properties of glue.

3 ex

FIELD: medicine.

SUBSTANCE: method involves applying surgical intervention and antitumor therapy. After having removed a part or the whole lung, mediastinum is opened by cutting out horseshoe-shaped or rectangular flap of mediastinal pleura and carrying out lymphodissection. Then, hemostatic sponge is placed in mediastinum. The sponge is impregnated with antitumor chemotherapeutical preparations in intraoperative mode. Pleura is sutured above the sponge. Another hemostatic sponge impregnated with cytostatic preparations in intraoperative mode is attached to visceral pleura of interlobular sulcus.

EFFECT: prolonged chemotherapeutical preparations delivery to malignant neoplasm foci or subclinical metastases.

FIELD: medicine, hematology, pharmacy.

SUBSTANCE: invention relates to the composition of factor VIII composed without addition of albumin and comprising the following excipients of composition in addition to factor VIII: from 4% to 10% of filling agent taken among group consisting of mannitol, glycine and alanine; from 1% to 4% of stabilizing agent taken among group consisting of sucrose, trehalose, raffinose, arginine; from 1 mM to 5 mM of calcium salt, from 100 mM to 300 mM of NaCl, and buffer agent for pH value maintenance about between 6 and 8. Alternatively, the composition can comprise from 2% to 6% of hydroxyethylstarch; from 1% to 4% of stabilizing agent taken among group consisting of sucrose, trehalose, raffinose, arginine; from 1 mM to 5 mM of calcium salt, from 100 mM to 300 mM of NaCl, and buffer agent for pH value maintenance between 6 and 8. In additional variant of realization of invention the composition can comprise: from 300 mM to 500 mM of NaCl, from 1% to 4% of stabilizing agent taken among group consisting of sucrose, trehalose, raffinose and arginine; from 1 mM to 5 mM of calcium salt, and buffer agent. The composition provides stability in the absence of albumin or other proteins.

EFFECT: valuable properties of compositions.

35 cl, 11 tbl, 7 ex

The hemostatic tool // 2242987
The invention relates to the field of medical pharmacology, namely organic geostatical used to stop the capillary and mixed hemorrhage in traumatic lesions of the skin and muscle tissue in surgical practice

FIELD: pharmaceutical industry, in particular agent for treatment of joint diseases in form of injections.

SUBSTANCE: claimed agent contains glucoseamine salt, preservative, non-ionic surfactant, in particular oleic acid and polyoxyethylated sorbitan monoether, and water.

EFFECT: agent for treatment of joint diseases of improved effectiveness combining chondroprotevtive action with high pharmacokinetic properties and biological availability.

3 cl, 3 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: remedy has saccharides like chondroitin sulfate (0.5-20.0% by mass) and salt of glycosamine (1.0-25.0% by mass), preservative (0.1-2.0% by mass), nonionogenic substance like monoester of oleic acid and polyoxyethylized sorbitan (1.0-5.0% by mass), and water (the rest).

EFFECT: increased active substances bioavailability and diffusion rate into articulation zone.

3 cl, 3 tbl

FIELD: medicine, in particular preparation of quick closing insulin preparations for treatment of diabetus mellitus.

SUBSTANCE: claimed method includes preparation of solutions containing insulin and ancillary substances, blending thereof, sterilizing filtration and bottling into flacks. Previously buffer solution containing 2.35-2.45 mg of disubstituted sodium phosphate; 2.25-3.0 mg m-cresol, and 15-17 mg of glycerol as calculated to 100 U of insulin is prepared, then insulin solution is prepared at 3.1-3.3 and added to buffer solution. Solutions are blended at agitation for 10-20 min, pH is adjusted to 7.2-7.4 and water is added up to finish insulin concentration of 100 IU/ml.

EFFECT: human gene engineered insulin of prolonged storage time without losses of physical, chemical and biological properties.

2 ex, 1 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to therapy of topical suppurative-inflammatory processes. Agent represents an aqueous isoosmotic solution comprising 0.25% of novocaine, 1% of cefazolin sodium salt and 0.77% of sodium chloride. Invention provides the development of optimal conditions for safety mechanical moving of agent in intercellular space under positive hydrodynamic pressure in the permanent state from the injection point in direction to side of deeply localized pathological focus and eliminates the pain component of the inflammatory response.

EFFECT: valuable medicinal properties of agent.

2 ex

FIELD: medicine, transfusion, infusion therapy.

SUBSTANCE: invention proposes antioxidant representing hydroxyethylated starch or pullulan chemically modified with steric-hindranced phenol. Fragment of steric-hindranced phenol represents β-(4-hydroxy-3,5-di-tert.-butylphenyl)-propionyl or β-(4-hydroxy-3,5-di-tert.-butylphenyl)-α-(N-benzoylamino)-acryloyl and its content is from 2 wt.-% up to limit solubility of polymer in water and doesn't exceed 10 wt.-% for modified hydroxyethylated starch and 12 wt.-% for modified pullulan. Plasma substitute showing antioxidant and antiradical activity represents indicated polymeric antioxidant in physiological solution or Ringer-Lock solution in plasma substitute based on the corresponding non-modified polymer. Also, invention describes a method for maintenance the level of arterial pressure and processes of antioxidant protection of body under condition of acute blood loss by using the indicated plasma substitute. As compared with analogs, new plasma substitute shows two kinds of activity: antioxidant and antiradical that are sufficient for operative increase of arterial pressure and its stabilization at the level of physiological norm, and for decreasing amount of free radicals and enhancing antioxidant protection of body in acute massive blood loss.

EFFECT: valuable medicinal properties of agents.

5 cl, 6 tbl, 4 ex

FIELD: organic chemistry, pharmacy.

SUBSTANCE: invention relates to a medicinal agent representing solution of the compound N-[O-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glycine of the formula (I):

in common with at least one regulator of pH value chosen from the group consisting of trisodium phosphate hydrate, sodium hydroxide and potassium hydroxide in the amount providing pH 7.0-9.0. Proposed medicinal agent represents injection formulation and designated for treatment of state with the proposed compound that is an inhibitor of enzyme elastase and improves the disease state. Also, invention relates to the ready medicinal formulation of this agent representing the injection formulation prepared by drying and freezing out. Invention provides acceptable solubility and stability of the compound (I) in solution and as a component of ready injection medicinal formulations.

EFFECT: improved and valuable pharmaceutical properties of medicinal formulation.

15 cl, 6 tbl, 1 dwg, 6 ex

FIELD: special compositions.

SUBSTANCE: invention relates to active composition for regional effect that comprises active compounds for regional effect and taken in the amount from about 0.001 to about 5 wt.-%, anionic surface-active substance taken in the amount from about 0.1 to about 15 wt.-%, hydrotrop taken in the amount from about 0.5 to about 35 wt.-%, water-soluble hydrogen-containing solvent taken in the amount from about 0.5 to about 25 wt.-%, and from 0 to about 5 wt.-% of secondary surface-active substance, and water. Also, invention relates to a method for surface cleansing and precipitation of active compound for regional effect on indicated surface. The composition provides rapid and effective precipitation of active compound for regional effect in combination with producing effective residual effect.

EFFECT: improved and valuable properties of compositions.

15 cl, 3 tbl, 29 ex

FIELD: organic chemistry, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical preparation comprising concentrated aqueous solution of α-2,4-disulfophenyl-N-tert.-butylnitrone disodium salt wherein the concentration of α-2,4-disulfophenyl-N-tert.-butylnitrone disodium salt in solution is in the ranges from 100 to 600 mg/ml, and pH value is in the range from 7 to 9.5. Also, invention relates to a method for preparing this preparation. Prepared solutions of α-2,4-disulfophenyl-N-tert.-butylnitrone disodium salt show high stability and elicit antibacterial properties that allow avoiding addition of preserve agents.

EFFECT: improved and valuable pharmaceutical properties of preparations.

17 cl, 16 tbl, 12 ex

FIELD: medicine, oncology, pharmacy.

SUBSTANCE: invention relates to medicinal agent for treatment of solid tumors. Agent comprises dispersion of paclitaxel microparticles stabilized with albumin in physiological solution wherein microparticles are taken in the concentration 2-8 mg/ml of this solution. Medicinal agent doesn't comprise surface-active substances and can be administrated safely into arteries directly that supply tumor-associated region sensitive to paclitaxel for short administration time in the range of some minutes, and this administration can be repeated some times.

EFFECT: valuable medicinal properties of agent.

2 cl, 5 ex

FIELD: medicine, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to a cerebral protective and stress-protective medicinal agent. Agent comprises an active base as a mixture thiotriazoline with piracetam and water for injection as a forming component. The proposed medicinal agent shows the enhanced bioavailability of active medicinal components, and it shows the cerebral protecting, stress-protective and anti-amnestic effect also.

EFFECT: valuable properties of agent.

12 tbl

FIELD: pharmaceutical industry.

SUBSTANCE: claimed complex contains vitamins such as B1, B2, B3 (nicotineamide), B5 (calcium pantothenate), B6, B9 (folic acid), B12, A, C, D3, E, beta-carotene, lycopitin, and minerals such as magnesium, copper, iodine, iron, molybdenum, selenium, calcium, phosphorus, chromium, zinc, and manganese. Complex is separated into two solid formulations taken at different time. The first solid formulations contains B1, B2, B3 (nicotineamide), B5 (calcium pantothenate), B6, B9 (folic acid) and minerals such as magnesium, copper, iodine, iron, molybdenum in specific component ratio; the second one contains A, C, D3, E, beta-carotene, lycopitin, and minerals such as selenium, calcium, phosphorus, chromium, zinc, and manganese in specific component ratio.

EFFECT: vitamin-and-mineral complex of improved antioxidant properties.

6 cl, 1 ex

Up!